Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

tarsus pharmaceuticals inc - TARS

TARS

Close Chg Chg %
70.22 -0.10 -0.14%

Closed Market

70.12

-0.10 (0.14%)

Volume: 370.83K

Last Updated:

Apr 2, 2026, 4:00 PM EDT

Trade Now

Company Overview: tarsus pharmaceuticals inc - TARS

TARS Key Data

Open

$69.06

 Day Range

69.01 - 71.37

52 Week Range

38.51 - 85.25

 Market Cap

$2.98B

Shares Outstanding

42.56M

 Public Float

39.92M

Beta

0.63

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.61

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

495.22K

  

TARS Performance

1 Week
 
 5.84%
 
1 Month
 
 -4.29%
 
3 Months
 
 -13.19%
 
1 Year
 
 49.13%
 
5 Years
 
 112.94%
 

TARS Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About tarsus pharmaceuticals inc - TARS

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

TARS At a Glance

Tarsus Pharmaceuticals, Inc.
15440 Laguna Canyon Road
Irvine, California 92618
Phone 1-949-409-9820 Revenue 451.36M
Industry Pharmaceuticals: Major Net Income -66,418,000.00
Sector Health Technology 2025 Sales Growth 146.708%
Fiscal Year-end 12 / 2026 Employees 370
View SEC Filings

TARS Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 7.58
Price to Book Ratio 10.146
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -44.633
Enterprise Value to Sales 6.838
Total Debt to Enterprise Value 0.027

TARS Efficiency

Revenue/Employee 1,219,891.892
Income Per Employee -179,508.108
Receivables Turnover 5.182
Total Asset Turnover 0.956

TARS Liquidity

Current Ratio 3.853
Quick Ratio 3.82
Cash Ratio 3.079

TARS Profitability

Gross Margin 93.202
Operating Margin -15.723
Pretax Margin -14.259
Net Margin -14.715
Return on Assets -14.068
Return on Equity -23.388
Return on Total Capital -15.574
Return on Invested Capital -18.377

TARS Capital Structure

Total Debt to Total Equity 24.179
Total Debt to Total Capital 19.471
Total Debt to Total Assets 14.648
Long-Term Debt to Equity 24.179
Long-Term Debt to Total Capital 19.471
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Tarsus Pharmaceuticals Inc - TARS

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
25.82M 17.45M 182.95M 451.36M
Sales Growth
-54.73% -32.42% +948.62% +146.71%
Cost of Goods Sold (COGS) incl D&A
955.00K 1.59M 12.83M 30.68M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
789.00K 877.00K 1.23M 1.82M
Depreciation
789.00K 744.00K 685.00K 855.00K
Amortization of Intangibles
- 133.00K 540.00K 961.00K
COGS Growth
-53.98% +66.81% +705.15% +139.23%
Gross Income
24.86M 15.85M 170.13M 420.68M
Gross Income Growth
-54.76% -36.23% +973.09% +147.27%
Gross Profit Margin
+96.30% +90.87% +92.99% +93.20%
2022 2023 2024 2025 5-year trend
SG&A Expense
87.57M 159.01M 290.70M 491.64M
Research & Development
42.62M 50.31M 53.39M 64.32M
Other SG&A
44.95M 108.70M 237.31M 427.32M
SGA Growth
+30.49% +81.58% +82.81% +69.13%
Other Operating Expense
- - - -
-
Unusual Expense
- 769.00K (376.00K) 2.15M
EBIT after Unusual Expense
(63.48M) (142.78M) (122.71M) (70.97M)
Non Operating Income/Expense
3.58M 10.23M 15.01M 15.54M
Non-Operating Interest Income
3.50M 10.34M 15.01M 15.75M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.20M 3.35M 7.85M 8.94M
Interest Expense Growth
- +52.16% +134.58% +13.84%
Gross Interest Expense
2.20M 3.35M 7.85M 8.94M
Interest Capitalized
- - - -
-
Pretax Income
(62.09M) (135.89M) (115.55M) (64.36M)
Pretax Income Growth
-350.88% -118.85% +14.97% +44.30%
Pretax Margin
-240.53% -778.89% -63.16% -14.26%
Income Tax
- - (4.00K) 2.06M
-
Income Tax - Current - Domestic
- - (4.00K) 2.06M
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(62.09M) (135.89M) (115.55M) (66.42M)
Minority Interest Expense
- - - -
-
Net Income
(62.09M) (135.89M) (115.55M) (66.42M)
Net Income Growth
-349.06% -118.86% +14.97% +42.52%
Net Margin Growth
-240.51% -778.89% -63.16% -14.72%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(62.09M) (135.89M) (115.55M) (66.42M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(62.09M) (135.89M) (115.55M) (66.42M)
EPS (Basic)
-2.522 -4.6248 -3.0729 -1.5896
EPS (Basic) Growth
-274.91% -83.38% +33.56% +48.27%
Basic Shares Outstanding
24.62M 29.38M 37.60M 41.78M
EPS (Diluted)
-2.522 -4.6248 -3.0729 -1.5896
EPS (Diluted) Growth
-274.91% -83.38% +33.56% +48.27%
Diluted Shares Outstanding
24.62M 29.38M 37.60M 41.78M
EBITDA
(61.92M) (142.28M) (119.34M) (69.15M)
EBITDA Growth
-436.08% -129.77% +16.12% +42.06%
EBITDA Margin
-239.86% -815.50% -65.23% -15.32%

Snapshot

Average Recommendation BUY Average Target Price 95.00
Number of Ratings 9 Current Quarters Estimate -0.145
FY Report Date 06 / 2026 Current Year's Estimate -0.593
Last Quarter’s Earnings -0.28 Median PE on CY Estimate N/A
Year Ago Earnings -1.59 Next Fiscal Year Estimate 3.057
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 9 9 9 7
Mean Estimate -0.14 -0.19 -0.59 3.06
High Estimates 0.03 0.07 0.33 4.34
Low Estimate -0.30 -0.34 -0.87 1.95
Coefficient of Variance -76.34 -61.83 -60.11 28.63

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 8 8 8
OVERWEIGHT 1 1 1
HOLD 0 0 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Tarsus Pharmaceuticals Inc - TARS

Date Name Shares Transaction Value
Mar 10, 2026 Jeffrey S. Farrow See Remarks 30,724 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Jeffrey S. Farrow See Remarks 19,306 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Bobak Azamian President/CEO and Board Chair; Director 96,723 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Bobak Azamian President/CEO and Board Chair; Director 60,776 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Aziz Mottiwala Chief Commercial Officer 30,724 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Aziz Mottiwala Chief Commercial Officer 19,306 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Dianne Whitfield Chief Human Resources Officer 27,310 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Dianne Whitfield Chief Human Resources Officer 17,161 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Elizabeth Yeu-Lin Chief Medical Officer 27,310 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Elizabeth Yeu-Lin Chief Medical Officer 17,161 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Sesha Neervannan Chief Operating Officer 27,310 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Sesha Neervannan Chief Operating Officer 17,161 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Bryan Wahl General Counsel 27,310 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 10, 2026 Bryan Wahl General Counsel 17,161 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Tarsus Pharmaceuticals Inc in the News